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It is still debatable whether the various isolates of murine leukemia-inducing  viruses 
(MuLV) I represent distinct viruses, isolates from different sources of the same virus, or 
closely related variants. The studies of Gross (1), designed to compare these viruses in 
terms of their morphology, chemical stability, and pathogenicity, failed to reveal sig- 
nificant differences.  Electron microscopic  observations have shown that all MuLV iso- 
lates are  enveloped, "C-type" particles (1,  2).  In addition, these particles are uni- 
formly susceptible to mild ether treatment (1, 3), share a common internal group-spe- 
cific antigen (4, 5), and are capable of inducing a wide spectrum of leukemias, namely 
lymphoid, myeloid, or stem cell leukemias among different susceptible mouse strains 
(1, 6). Only the MuLV strains isolated by Friend (7) and Rauscher (8)  consistently 
induce a  particular type of leukemia, an erythroleukemia, in all susceptible mouse 
strains. The  capacity  of  these  virus isolates  to  rapidly  induce erythroleukemia is 
thought to be a  property of spleen focus-forming virus (SFFV), which is regularly 
accompanied by a lymphatic leukemia-inducing  helper virus (LLV-F or LLV-R) in the 
Friend or Rauscher virus complex, respectively (9). 
Methods used for  the classification of leukemia viruses of avian origin have been 
based on their host range in genetically different types of  chicken cells,  and their 
patterns of ifiterference among one another. Results from these tests were  then con- 
firmed by virus neutralization tests with specific antisera (10). While leukemia viruses 
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of murine origin  exhibit both host-range differences and viral interference patterns, 
such  parameters cannot be utilized for classifying  MuLV's. For example, naturally 
occurring  MuLV strains fall into two categories with respect to their growth in mouse 
embryo (ME) cells of NIH Swiss (N-type) or BALB/e (B-type) mice (11). "N-tropic" 
viruses initiate infection  more efficiently on N-type than on B-type ME cells, while 
"B-tropic" viruses show  the reciprocal pattern. However, these host-range patterns 
are not stable, since continued passage of an MuLV strain in the restrictive host cell 
type results in the recovery of virus that infects both cell types with equal efficiency. 
Such virus is designated "NB-tropic" (11). 
Interference tests are complicated by a lack of specificity, for such unrelated agents 
as an arbovirus (12) and a parainfluenza virus (13) inhibit MuLV replication and leu- 
kemia induction in vivo. Therefore, a classification  for MuLV isolates  depends on an 
immunologic  approach. Studies  by Old et al. (14, 15) have revealed two broad cate- 
gories of virus-induced murine leukemias,  those possessing the Gross or G antigen(s), 
and those possessing the Friend-Moloney-Rauscher or FMR antigen(s). However, the 
more subtle antigenic relationships  among the leukemia viruses that induce tumors of 
G or FMR specificity remained largely unknown. 
To classify the  MuLV's according to  their  type-specific (virus-bound),  en- 
velope antigens, we wished to apply the technique of antigenic analysis by neu- 
tralization kinetics, a method previously used to study the antigenic relationship 
between  Friend  SFFV  and  Rauscher  SFFV  (16).  However,  the  spleen focus 
assay method (17) used in this study could not be directly applied to MuLV's 
other  than  SFFV.  Until  the recent work of Rowe et al.  (18),  an enumerative 
assay for MuLV's other than SFFV was not available. Therefore, we utilized 
the observation  that  the  Fv-P gene  of  B-type mice  (19,  20)  interferes  with 
LLV-F, the naturally occurring helper virus for SFFV in the Friend virus (FV) 
complex. Preliminary  results  (21)  indicated  that  mixed infection  of neonatal 
BALB/c mice with FV complex (containing SFFV  and N-tropic LLV-F) and 
an antigenically distinct MuLV resulted in  antigenic alteration of SFFV. We 
refer to such virus preparations as pseudotypes of Friend SFFV,  abbreviated 
SFFV(MuLV)  following the  example of Hanafusa et al.  (22)  with  Rous  sar- 
coma  virus.  The  experiments  reported  here  confirm  the  observation  that 
SFFV(MuLV)  pseudotypes can be prepared in vivo. Further,  the patterns by 
which  a  given SFFV(MuLV)  pseudotype was neutralized  by specific antisera 
identified  the  antigenicity  of  the  corresponding  MuLV  used  to  prepare  the 
pseudotype.  Accumulated  data  made it possible to  classify  several  MuLV's 
according to their virus-bound,  type-specific envelope antigens. 
Materials and Methods 
Anlmals.--Neonatal BALB/c and C3H/He mice and 6-8-wk old male BALB/cCr, DBA/ 
2Ha, and female Ha/ICR (random-bred) Swiss mice were obtained from the West Seneca 
Animal Production Unit, Roswell Park Memorial Institute,  Buffalo, N.Y. Female Sprague- 
Dawley rats were obtained from the Charles River Breeding Laboratories, Inc., Wilmington, 
Mass. 
Viruses.--SFFV, as contained in the Mirand strain (23) of the FV complex,  was originally 834  MuLV  TYPE-SPECIfIC  CLASSIFICATION 
obtained from Dr.  Charlotte Friend and has now undergone over 200  cell-free passages in 
Ha/ICR Swiss mice. All such SFFV stocks initiate infection 40-100 times more efficiently in 
Ha/ICR Swiss and DBA/2 mice than in BALB/c mice (24)  and are therefore designated as 
having an N-tropic (11) host range. BALB/c mice and other B-type mice are significantly less 
sensitive to  N-tropic  viruses.  The  multiple-hit,  dose-response relationships observed when 
SFFV is titrated in BALB/c mice (24) suggests that B-type mice inhibit the N-tropic helper 
virus (LLV-F) indigenous to the FV complex (9). 
SFFV, as contained in the Rauscher virus (RV) complex, was originalb, obtained from Dr. 
F. Rauscher, and has now undergone 10 cell-free passages in adult Ha/ICR Swiss mice. This 
RV complex, although originally NB-tropic, now initiates spleen focus formation 50 times more 
efficiently in DBA/2 mice than in BALB/c mice and shows a two-hit, dose-response relation- 
TABLE  I 
Identification and Origin of Viruses Used to Prepare Pseudotypes of SFFV 
Titer helper 
MuLV isolate*  Origin (reference)  Method  used to remove  units 
SFFV  (ttU)/ml 
LLV-F~: 
LLV-R 
RPV(=  LLV-F) 
RichLV 
MolLV 
BMLV 
SimLV 
Friend (7, 9) 
Rauscher (8, 9) 
334C 
GLV 
GiLV 
Other murine viruses 
MPV 
LCM 
Rowson and Parr  (27, 
28) 
Rich et al.  (29)  1 
Moloney (30)  / 
Breyere et al.  (31) I 
Spontaneous (21)  I 
Buffett et al.  (32) 
Gross (33)  j 
Graffi (34) 
Molomut-Padnos (26) 
Traub (35) 
C57BL passage 
Sucrose gradient 
End point dilution 
Free of detectable 
SFFV when isolated 
50,000 
20,000 
15,000 
25,000 
30,000 
5000 
20,000 
14,000 
30,000 
10,000 
* Most MuLV isolates were maintained in B-type mice; all MuLV's demonstrated an NB- 
tropic host range before use in pseudotype production. 
:~ This virus is referred to in the text as either LLV-F or simply LLV. 
ship when titrated in BALB/c mice (R. J. Eckner, unpublished observations). Apparently the 
natural helper virus (LLV-R) in the RV complex ac luired an N-tropic host range after pro- 
longed passage in Swiss mice in our laboratory. 
In an attempt to prepare pseudotypes of Friend SFFV, several MuLV and other viruses of 
murine origin were mixed with N-tropic FV complex and injected into B-type mice. The virus 
preparations used are listed in Table I with their titers in helper units per milliliter (see section 
on Virus Titrations). All MuLV stocks were maintained in this laboratory by serial passage of 
20% (w/v) cell-free extracts of leukemic tissue into newborn BALB/c mice and were stored at 
--196°C. Lymphocytic choriomeningitis (LCM)  virus, a  known arenovirus (25),  was chosen 
as a nonlethal, nonleukemogenic "control" murine virus, as was Molomut-Padnos virus (MPV), 
a leukopenia-inducing, RNA-containing virus (26)  that may be related to LCM virus, but is 
still unclassified. Both virus preparations had titers  >107 IDs0/ml  in adult  Swiss  mice,  and 
were kindly provided by Dr. J. Hotchin (Virus Laboratory, State of New York Department of ROBERT  J.  ECKNER  AND  RICHARD  A.  STEEVES  835 
Health, Albany, N.Y.)  and Dr. M.  Padnos  (Waldemar Medical Research Foundation, Inc., 
Long Island, N.Y.), respectively. 
Virus Titrations.--SFFV  in the FV or the RV complex was titrated in vivo with the spleen 
focus assay method (17). Briefly, 0.5-ml samples of diluted SFFV were injected intravenously 
into susceptible DBA/2 mice. 9 days later, their spleens were removed and fixed in Bouin's 
solution. Discrete foci on the splenic surface were counted macroscopically, and virus titers 
(mean No. of loci per spleen )< dilution factor) were expressed in focus-forming units (FFU)/ 
ml, where one FFU is that amount of virus required to induce an average of orAe focus per 
spleen. 
All other MuLV stocks were free of detectable SFFV and had demonstrable helper activity 
for SFFV. Their origin and quantification with a  helper virus assay method have been de- 
scribed (36).  Briefly, a  constant amount of FV complex containing helper-dependent "indi- 
cator" SFFV was added either to potential helper virus, serially diluted from 1:5 to 1:40 in 
phosphate-buffered saline (PBS), or to PBS alone. Samples of 0.5 ml were then injected into 
the lateral tall vein of male BALB/c mice, seven per group. After 9 days the mice were killed, 
their spleens were fixed in Bouin's fluid, and the numbers of discrete foci on the splenic surface 
>0.5 mm in diameter were counted macroscopically. The mean number of foci per spleen for 
each group,  when multiplied by the SFFV dilution factor, gave an estimate of the titer of 
SFFV with or without diluted helper virus. The difference between these two estimates (i.e. 
the helper virus activity in AFFU/ml) was then related on a log/log plot to the dilution factor 
of the helper virus. The linear extrapolation for the helper activity of undiluted virus is ex- 
pressed in helper units (HU), where one HU is that amount of virus required to increase the 
estimated titer of SFFV by one FFU/ml. 
Pseudotype Production.--MuLV  pseudotypes of Friend SFFV were prepared in vivo as sum- 
marized in Fig. 1. Briefly, SFFV (as contained in N-tropic FV complex) was diluted 1 : 100 into 
various NB-tropic MuLV helper stocks, so that the mixture contained 103 FFU/ml of SFFV 
(as titrated in DBA/2 mice) and  10  ~ HU/ml of MuLV. We inoculated 5-10-day old BALB/c 
mice iutraperitoneally with 0.2 ml of this mixture, and 20-25 days later the enlarged spleens 
were pooled, from which cell suspensions (20% w/v) were made in McCoy's medium with 3% 
fetal calf serum. The suspensions were centrifuged at 2400 g  for 10 rain, and the supernatant 
fluids (referred to as spleen extracts) were either used immediately for a  second passage or 
stored at --196 °C. The same protocol was followed with each SFFV(MuLV) preparation for 
a  total of two to three passages in order to reduce the relative concentration of LLV-F in- 
digenous to the FV complex. 
Preparation of Murine Antisera.--Moloney,  Rich, Breyere-Moloney, and  Graffi antisera 
were  prepared  from adult  BALB/c mice given 20 weekly  intraperitoneal injections of  108 
frozen-thawed BALB/c lymphoma cells induced by MolLV, RichLV, BMLV, and GiLV,  re- 
spectively. In addition, Friend LL  and SimL antisera were prepared from adult Swiss mice 
given 16 immunizations of  10  ~ Swiss  lymphoma cells induced by LLV-F or  SimLV, respec- 
tively. Swiss mice injected by the same schedule with normal Ha/ICR Swiss spleen cells did not 
produce alloantibodies in quantities sufficient to neutralize SFFV. Within each series of im- 
munizations, the mice were bled 7 days after the last injection. The sera were pooled, heated at 
56°C for 30 min to eliminate complement activity, and stored at --70°C. All sera used demon- 
strated virus-neutralizing activity against the MuLV pseudotype of SFFV corresponding to 
the MuLV-induced lymphoma cells used as pretreatment material. Also,  this  activity was 
completely removed by three serial absorptions with appropriate MuLV-induced lymphoma 
cell homogenates. As a control, normal mouse serum (NMS) was prepared from an untreated 
group of Swiss mice. 
Gross Typing Serum.--In an attempt to prepare specific neutralizing antiserum directed 
against  Gross virus, Sprague-Dawley rats were immunized with 5 )< 10  s Gross virus-induced 
BALB/c  lymphoma cells (spleen and thymus). The first injection (1.5 ml intraperitoneally) 836  MuLV TYPE-SPECIFIC CLASSIFICATION 
included 0.5 ml of complete Freund's adjuvant.  The second, third, and fourth injections (0.5 ml 
intramuscularly)  were given on days  10, 25, and 40, respectively. 7 days after  the last  treat- 
ment,  the animals were bled and  sera were prepared  as  stated  above.  Finally,  the Gross 
antiserum  was serially absorbed 12 times with normal BALB/c spleen cells and was tested for 
its neutralizing capacity against different pseudotypes of SFFV. 
Virus Neutralization.--The antigenicity  of all SFFV preparations  was tested by following 
their neutralization  kinetics in vitro with specific antisera  (16). Antiserum (final dilution 1 : 10 
or 1:20) was prewarmed  to 37°C, and at time zero a given SFFV preparation  (103 to 5 X  104 
FFU/ml) was combined with the diluted serum and incubated in a 37°C water bath. At 10- 
min intervals over a 60 min period, a sample was removed from the reaction tube, diluted in 
ice-cold PBS (pH 7.2), and immediately assayed in groups of seven DBA/2 mice by the spleen 
focus assay method. The fractional virus survival for each incubation period was calculated by 
dividing the corresponding residual virus  titer  by the original virus  fiter  (SFFV incubated 
with NMS for 60 min at 37°C). Serum potencies are expressed in terms of the inactivation 
constant K, determined as follows: K  =  (D/t)Log~ (Vo/Vt), where D = serum dilution, Vo = 
original virus titer, and Vt = virus titer at reaction time t. 
RESULTS 
Scheme for Producing MuL V  Pseudotypes of SFFV.--It has been shown that 
all N-tropic strains of FV complex tested are defective for spleen focus forma- 
tion in B-type mice  (37).  This  defectiveness  of SFFV,  together with  the  ob- 
servations  that  (a)  SFFV's antigenicity  appears  to be  controlled  by its  asso- 
ciated  helper  virus  (21)  and  (b)  most MuLV preparations  express  significant 
levels of helper activity for SFFV, suggested that MuLV pseudotypes of SFFV 
could be prepared in vivo. Fig.  1 summarizes a proposed scheme for preparing 
pseudotypes in  neonatal  BALB/c mice.  In this  example,  SFFV  and  N-topic 
LLV (as contained in FV complex) are mixed with a preparation of NB-tropic 
MolLV.  The  proposed  pseudotype  recovered,  SFFV(MolLV),  has  both  the 
antigenicity and the host range of the MolLV helper virus. 
The validity of this pseudotype hypothesis is dependent upon the demonstra- 
tion that: (a) all MuLV preparations used can replicate efficiently (i.e. they can 
replicate within 20 days of infection, to titers  above the input virus inoculum 
so that MuLV envelope antigens would be available in B-type mice for pseudo- 
type production); (b) coinfection of mice with SFFV and antigenically distinct 
MuLV  helpers  results  in  an  antigenic  alteration  of  SFFV;  (c)  the  antigenic 
alteration is not merely apparent, due to nonspecific virus interactions within a 
common host, but is a specific change that occurs only when LLV-F is inhibited 
in mice coinfected with an antigenically distinct helper virus. 
Replication  of MuLV Helper  Viruses  in  Neonatal BALB/c Mice.--Studies 
concerning  the  growth  of LLV-F in  adult  BALB/c mice  (9)  suggested  that 
MuLV helpers could only replicate transiently in adult mice, with subsequent 
loss  of  demonstrable  virus  beyond  14  days  postinfection.  Therefore,  before 
attempting  to produce pseudotypes of SFFV,  we had  to determine  if MuLV 
preparations  could  replicate  efficiently  in  neonatal  BALB/c mice for  a  more 
prolonged  period  of  time.  To  follow  the  growth  kinetics  of  several  MuLV ROBERT  J.  ECKNER  AND  RICHARD  A.  STEEVES  837 
stocks (candidates for pseudotype production), we inoculated neonatal (5-10- 
day old)  BALB/c mice intraperitoneally with  MolLV (3  X  103 helper  units 
[HU]/animal), or LLV-R (103 HU), or GLV (3  X  103 HU). At various  times 
after infection, groups of three to four mice were sacrificed, the enlarged spleens 
were pooled, and cell suspensions (1  spleen equivalent/ml medium) were pre- 
pared in  McCoy's medium with 3%  fetal calf serum. The suspensions were 
centrifuged at 2400 g for 15 rain and the supernatant fluids were assayed for 
helper activity for SFFV. As shown in Fig. 2, peak titers for MolLV, LLV-R, 
and  GLV  were observed from  14  to  21  days postinfection, and  diminishing 
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FIG.  1.  Scheme  for  producing  MuLV  pseudotypes  of  Friend  SFFV.  Helper-dependent 
SFFV is diluted 1:100 into stock helper virus (> 1@ HU) and 0.2 ml of this mixture (200 
FFU, as fitrated in DBA/2 mice) is injected intraperitoneally into 5-10-day old BALB/e 
mice. Pseudotype virus is harvested 20-25 days postinfection  from the spleens  of infected mice. 
titers were observed for MolLV and  GLV from 18 to 35  days postinfection. 
Similarly, titers  >  104 HU/spleen were recovered from BALB/c mice 2-3 wk 
postinfection at 5-10 days of age with LLV-F, RichLV, RPV, GiLV, SimLV, 
BMLV, and 334C virus. Therefore, the readily detectable helper activity for 
SFFV seen with all MuLV stocks tested suggests  that  they can replicate effi- 
ciently (as defined above) in neonatal BALB/c mice. 
Eqiciency and Stability of SFFV Antigenic Alteration.--In  a  preliminary 
study (21) we demonstrated that the antigenicity of SFFV can be altered by 
serially passaging a mixture of SFFV and an antigenically distinct helper virus 
(334C) in newborn BALB/c mice. In the present study, the efficiency of SFFV 
antigenic alteration was  determined quantitatively after each of three serial z  10  5 
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passages with MolLV in neonatal BALB/c mice. MoILV was chosen because of 
its  efficient  helper  activity for  SFFV,  and  because  preliminary studies  with 
Moloney  antiserum  suggested  that  MolLV  was  antigenically  distinct  from 
SFFV(LLV). 
New SFFV stocks were prepared by coinfecting 5-10-day old BALB/c mice 
with helper-dependent SFFV and MolLV helper (Fig. 1). At each passage level, 
the  antigenicity  of  the  new  SFFV  preparation  was  tested  by observing  the 
kinetics of neutralization of SFFV in vitro bv specific Friend or Moloney typing 
antiserum.  As  shown  in  Table  II,  Friend  typing  antiserum  neutralized  the 
source material for these experiments, SFFV(LLV), while Moloney antiserum 
had  no  neutralizing  activity for  this  same  preparation  of  Friend  SFFV.  In 
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FIG. 2.  Kinetics of MuLV replication in neonatal BALB/c mice. Helper activity of MolLV 
(e), LLV-R (O), and GLV (A) is shown as a function of time after infection with  >10  3  HU 
of potential helper virus. 
contrast, SFFV prepared from neonatal BALB/c mice after one passage in the 
presence of MolLV (PI:MolLV) was neutralized by both Friend and Moloney 
antisera. This result suggests the presence of two antigenically distinct  SFFV 
populations,  or the existence of SFFV particles with  a  mosaic of LLV-F and 
MoILV antigens in their envelope (38). Finally, SFFV prepared after two and 
three passages in the presence of MolLV (P2:MolLV and P3:MolLV,  respec- 
tively) was effectively neutralized only by the Moloney antiserum. 
These  observations  indicate  that  mixed  infection  of  BALB/c  mice  with 
SFFV(LLV)  and MolLV results in  the appearance of a  pseudotype of SFFV 
which carries the Moloney type-specific antigen(s) in its envelope. The complete 
loss of antigen detected by the Friend  typing antiserum suggests  (a)  that N- 
tropic LLV-F indigenous  to the FV complex has been functionally eliminated ROBERT  J.  ECKNER  AND  RICHARD  A.  STEEVES  839 
after two  passages with  MolLV  and  (b)  that  the envelope of the pseudotype 
virus,  SFFV(MolLV),  is  homogeneous,  i.e.,  it  does  not  contain  antigen(s) 
characteristic of both Friend and Moloney virus. 
We also examined the stability of SFFV antigenic alteration, for this altera- 
tion  might  represent  a  genetic  change,  such  as  recombination  (39)  between 
SFFV and MolLV helper. Recombinants should be relatively stable with respect 
to  their  envelope  antigens.  We  tested  this  possibility by  analyzing the  neu- 
tralizable  antigens  of  new  SFFV  stocks  prepared  from  neonatal  BALB/c 
mice infected with  SFFV(MolLV)  only, or from BALB/c mice infected with 
TABLE II 
Efficiency and Stability of SFFV Antigenic Alteration 
Infecting viruses  Virus harvested 
passage N o. :  helper virus 
Neutralization by specific typing 
antisera (K :t: sE)* 
Friend  Moloney 
SFFV(LLV-F)  P0:LLV  1.37  ±  0.07 
P0:LLV q- MolLV  PI:MolLV  1.66  ±  0.12 
p1 :MolLV q- MolLV  P2 :MolLV~  0 
P2:MolLV -/- MolLV  P3:MolLV:~  0 
SFFV(MolLV) passaged in BALB/c mice with no helper virus added 
P2 :MolLV only  P1 :-  0 
P1 :-  only  P2 :-  0 
P2 :-  only  1"3 :-  0 
SFFV(MolLV) passaged in ]~ALB/c mice with LLV-F added 
P2:MolLV ~- LLV-F  1"1:LLV-F  1.27  4-  0.12 
PI:LLV  -J- LLV-F  1"2:LLV-F  1.41  4-  0.10 
0 
0.28  4-  0.04 
1.21  4-  0.05 
1.13  4-  0.04 
0.23  -4- 0.09 
0.47  -4- 0.05 
1.09  ±  0.09 
* Virus-neutralizing activity is expressed in terms of the inactivation constant K. Each K 
value was obtained by following the neutralization kinetics of SFFV preparations by specific 
antiserum at 10-min intervals for a total of 60 rain. 
These SFFV preparations are identified as MolLV pseudotypes and abbreviated SFFV- 
(MolLV). 
both SFFV(MolLV) and  104 HU  of NB-tropic LLV-F. In the absence of con- 
tinued  mixed  infection  of  BALB/c  mice  with  SFFV(MolLV)  and  MolLV 
(middle section of Table II), pseudotype virus was antigenically stable. Only 
Moloney antiserum neutralized these SFFV preparations. Both first and second 
passage viruses (P l:  and P2:-)  were low in titer and were prepared as 50% 
(rather than 20 %) spleen extracts. An excess of viral antigen in these prepara- 
tions might explain the apparently decreased K  values observed. SFFV(MolLV) 
prepared as a  20%  spleen extract after a  third passage with no MolLV helper 
added also proved to be antigenically stable. However, this antigenic stability 
was conditional, since SFFV(MolLV) was easily converted back to the LLV-F 
type  (lowest part of Table II)  after only one  passage in  BALB/c mice with 840  MFI.V  TYPE-SPI~CIFIC  CLASSIFICATION 
NB-tropic LLV-F (Pl :LLV-F). The antigenic stability of SFFV(MolLV) may 
be the result of substitution  by MolLV for LLV-F in  the FV complex, since 
NB-tropic MolLV replicates efficiently, in BALB/c mice,  as  demonstrated  in 
Fig.  2,  and  N-tropic LLV-F is  functionally eliminated.  The antigenic inter- 
conversion  between  LLV-F  and  MolLV  types  demonstrates  that  SFFV  is 
defective with respect to the expression of neutralizable envelope antigens, but 
this does not rule out the possible existence of a minor fraction of recombinants 
not detectable in our system. 
Requirements for  the  Produclion  of  SFFV  Pseudotypes.--The  possibility 
TABLE  III 
Requirements for A Iteration qf SFF V Envelope A ntigens 
SFFV(LLV F) passaged 
in viw~;t with 
SFFV(LLV-F) mixed in 
vitro with 
i Candidate 
!  Helper virus  Neutralization  of SFFV by specific 
antisera  (K 4-  s~)* 
Treatment  MPV§ 
No helper 
added 
LLV F 
MolLV 
MolLV 
MPV 
MolLV 
MolLV 
None 
None 
Heat inactivated at 
56°C for 60 min 
None 
Incubated  with SFFV 
at 37°C for 30 min 
Pelleted with SFFV at 
150,000  g for 90 min 
Helper 
.ctivity 
HU/mI 
80,000 
30,000 
0 
! 
0 
30,000 
35,000 
! 
Friend  Moloney 
1.30  ::~ 0.07  0 
1.92  =:  0.18  0 
0  1.01  ±  0.07 
1.70  ::t: 0.07  0 
1.61  ::t- 0.35  NT 
1.45  :t=  0.10  0 
1.19  -1=  0.06  0 
0 
0 
NT 
NT 
0 
NT 
NT 
NT  =  not tested. 
* Virus-neutrallzing activity is expressed in terms of the inactivation constant K. Each K  value was obtained 
by following the neutralization kinetics of SFFV preparations by specific antiserum at 10-rain intervals for a total 
of 60 min. 
All in vivo growth of SFFV comprised two serial passages with the helper virus candidate indicated. 
§ MPV antiserum, provided by Dr. M. Padnos,  was prepared from a rabbit immunized with HeLa cell-grown 
MPV and has a virus neutralization  titer  > 10  4 
existed  that SFFV antigenic alteration could have resulted from incorporation 
into the SFFV virion of helper MuLV envelope antigen  that was present in the 
cell as a result of the initial infectious event (i.e., antigen  that  did  not require 
MuLV  synthesis).  To  test  this  possibility,  we  passaged  SFFV  serially  in 
BALB/c mice which were also injected with heat-inactivated MolLV (56°C for 
60  min).  After  two  such  passages,  conversion  to  the  Moloney  type  was  not 
observed (Table III). As a control, SFFV(LLV)  was grown with an NB-tropic 
strain of LLV-F. This SFFV preparation was also neutralized only by Friend 
LL antiserum. In agreement with previous data,  SFFV was readily converted 
to the Moloney pseudotype when the MolLV preparation used was infective. 
This  indicates  that  the  acquisition  of  distinct  new  envelope  antigens  is  de- 
pendent upon the replicative capacity of MolLV. ROBERT  J.  ECKNER  AND  RICHARD  A.  STEEVES  841 
To  determine  if  SFFV  pseudotypes  could  be  prepared  by  using  murine 
viruses other than leukemia viruses, SFFV stocks were also prepared after two 
serial  passages in  BALB/c  mice with  either  MPV  or LCM virus.  Although 
MPV is known to interfere with  Friend  and Rauscher SFFV-induced  spleno- 
megaly and  spleen focus formation  (R.  J.  Eckner,  unpublished  observations; 
and  personal  communication from Dr.  M.  Padnos),  we were able  to recover 
SFFV from neonatal BALB/c mice coinfected with MPV. This SFFV prepara- 
tion was antigenically indistinguishable from the source material,  SFFV(LLV). 
Both were strongly neutralized by Friend LL antiserum, while MPV antiserum 
failed  to neutralize  either  SFFV  preparation  (Table  III). Attempts  to  grow 
SFFV  with LCM  virus in  BALB/c mice were not  successful,  as LCM  virus 
interfered strongly with  SFFV. 
TABLE  IV 
Effect of Host-Range Control for LLV-F Expression on SFFV(MoILV) Pseudotype Production 
Infecting viruses* 
N-tropic SFFV(LLV-F) -/- 
MolLV 
NB-tropic SFFV(LLV-F) q- 
MolLV 
N-tropic SFFV(LLV-F) q- 
MolLV 
Host (genotype) 
C3H/He (Fv-1 n, Fv-F  ~) 
BALB/c (Fv-1 b, Fv-1 b) 
BALB/c (Fv-1 b, Fv-1 b) 
Neutralization by specific typing 
antisera  (K =t= SE); 
Friend 0.40  Moloney 
2.14  4-  0.33  4-  0.07 
>2.0  0.12  4-  0.06 
0  1.20  -4- 0,05 
* All in vivo growth of SFFV comprised two serial passages with  10  4 HU of NB-tropic 
MolLV. 
Virus-neutralizing activity is expressed in terms of the inactivation constant K. Each K 
value was obtained by following the neutralization kinetics of SFFV preparations by spe- 
cific antisera at 20-min  intervals for a total of 60 min. 
The possibility of antigenic alteration  due  to interviral aggregates  between 
SFFV and MolLV was also tested. SFFV was either  incubated with  >  104 HU 
of MolLV in vitro for 30 rain at 37°C, or centrifuged with MolLV at 105,000  g 
for 90 min (Spinco rotor No. 40;  Spinco Division, Beckman Instruments,  Inc., 
Fullerton,  Calif.)  and  resuspended  to  the  original  SFFV  volume. These  pro- 
cedures failed to demonstrate any conversion of SFFV(LLV)  to the Moloney 
type (lower section of Table III). 
Finally, it is implied in the pseudotype hypothesis (Fig.  1)  that pseudotype 
production would require inhibition of the natural helper virus in the FV com- 
plex, LLV-F. For the Fv-1 gene to effect this inhibition,  the b allele should be 
expressed and the FV complex should be N-tropic. It was possible to test this 
requirement for pseudotype production by analyzing the neutralizable envelope 
antigens  of  SFFV  stocks prepared  from:  (a)  neonatal  C3H/He  mice  (Fv-P  ~, 
Fv-1  "~) infected with N-tropic FV complex and  104 HU of NB-tropic MolLV; 842  MULV TYPE-SPECIFIC CLASSIFICATION 
(b)  neonatal  BALB/c mice (Fv-P, Fv-P)  infected  with  BALB-adapted  (NB- 
tropic) FV complex and 104 HU of NB-tropic MolLV; or (c) neonatal  BALB/c 
mice infected with N-tropic FV complex and  104 HU of NB-tropic MolLV. In 
the first case (a),  the Fv-1  b gene is absent, while in the second (b), Fv-1 b should 
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FIG. 3.  Neutralization  kinetics of Friend SFFV incubated  with type-specific murine anti- 
sera. e, Friend LL antiserum, K  =  1.92 4- 0.18; O, SimL antiserum, K  =  1.55 4- 0.09; A, 
Moloney antiserum, K  = 0; A, Rich antiserum, K  = 0.12 4- 0.03. 
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FIG. 4.  Neutralization  kinetics of the Moloney pseudotype of SFFV, SFFV(MolLV), in- 
cubated with type-specific murine antisera.  0, Friend LL antiserum, K  =  0.33 4- 0.07; O, 
SimL antiserum, K  =  0; A, Moloney antiserum, K  =  1.01 4- 0.07; /k, Rich antiserum, K  = 
0.50 4- 0.06. 
be unable to confer resistance to LLV-F since the helper has an  NB-tropic host 
range. Virus neutralization  tests with specific Friend or Moloney typing  anti- 
serum confirmed this prediction  (Table IV), for SFFV(LLV-F) was  effectively 
converted to the Moloney type only when the Fv-1  b allele  was present  and able 
to confer resistance  to endogenous N-tropic LLV-F of the FV complex. ROBERT  J.  ECKNER  AND  RICHARD  A.  STEEVES  843 
MuL V  Type-Specific Envelope Classification.--With  the requirements for and 
efficiency of pseudotype production established,  nine different  SFFV(MuLV) 
pseudotypes were prepared.  We then analyzed the neutralizable antigen(s)  of 
each pseudotype by observing  the kinetics  of neutralization with a panel of 
type-specific antisera.  The patterns by which  a given SFFV(MuLV) pseudo- 
type was  neutralized allowed us  to  identify the  virus-bound  (type-specific) 
envelope antigens of the particular MuLV used. This technique is presented  in 
Figs.  3  and 4, which  demonstrate that LLV-F and MolLV  pseudotypes are 
antigenically distinct.  SFFV(LLV-F)  was  effectively  neutralized by  Friend 
TABLE V 
Neutralization by Type-Specific Antisera  of MuLV Pseudotypes of Friend SFFV 
Serum inactivation  constant  (K4-sE)* 
MuLV 
pseudotype 
SFFV(MuLV) 
SFFV(GLV) 
SFFV(LLV-F) 
SFFV(RPV) 
SFFV (GiLV) 
SFFV (SimLV) 
SFFV (MolLV) 
SFFV (LLV-R 
SFFV (BMLV) 
SFFV- 
(RichLV) 
SFFV(334C) 
Gross:~ 
antiserum 
0.52  4-  0.07 
0.07  4-  0.02 
0.11  4-  0.05 
0.12  4-  0.03 
0.24  4-  0.14 
0.12  4-  0.071 
0.07  4-  0.04 
0.08  4-  0.021 
0.25  4-  0.04[ 
Friend LL 
antiserum  anl 
0 
1.92  4-  0.18  1.55 
1.43  4-  0.04  1.26 
1.09  4-  0.08  1.75 
1.71  4-  0.14  2.53 
0 
2.84  4-  0.40  2.75 
2.06  4-  0.18  2.63 
0.31  4-  0.05  3.50 
1.47  4-  0.1511 
•  Moloney 
um  antiserum 
0 
0.09  0 
0.05  0 
0.07 0.03  ±  0,005 
0.48  0 
1.13  ±  0,02 
0.42 0.33  4-  0.03 
0.41 0.26  4-  0.04 
0.07 0.46  4-  0.05 
0.06  4-  0.03 
Rich 
antiserum 
0 
0.12  4-  0.03 
0.24  4-  0.02 
0.23  4-  0.06 
0 
0.50  4-  0.07 
0.44  4-  0.12 
E).46 4-  0.03 
1.22  4-  0. 002 
~0.44 4-  0.05 
Breyere-  Grafft 
Moloney  antiserum 
antiserum 
_  __]___ 
000  0.14  0  0  0 
0  ±  0.03 
0  I  0 
0  I  o 
0.32  i  4-  0.0510.11  0.01 
0,39  4-  4-  0.04 0.29  0.04 
0  0.39  4-  0.02 
0  0 
* Virus-neutralizing activity is expressed in terms of the inactivation constant K. Each K  value was obtained 
by following the neutralization  kinetics of SFFV preparations  by specific antiserum at  10-min intervals for a 
total  of 60 min. 
~: In contrast to other antisera (murine), Gross antiserum was prepared from rats  immunized against  GLV-in- 
dnced, BALB/c lymphoma cells. Serial absorption with normal BALB/e spleen cells resulted in greatly decreased 
K  values (from >2.0 to <0.25) against SFFV(LLV-F) and other SFFV(MnLV)  pseudotypes,  while the K  value 
against SFFV(GLV) decreased only fourfold. 
§ Rauscher virus complex and SFFV(LLV-R) gave identical results. 
l[ ThisK value was calculated from the initial slope of the neutralization curve since the virus became resistant 
to further neutralization after 15 rain. 
LL  and  SimL  antisera  (Fig.  3),  while  SFFV(MolLV)  was  effectively  neu- 
tralized  only by Moloney and  Rich  antisera  (Fig.  4).  With  this  particular 
SFFV(MolLV)  preparation,  Friend LL antiserum showed some neutralizing 
activity (K =  0.3), but four other SFFV(MolLV)  preparations tested were not 
neutralized by this same Friend LL antiserum (K =  0). 
Further analysis  of the neutralizable  envelope antigens  of these  and other 
SFFV(MuLV) pseudotypes  made  possible  a  "type-specific" SFFV(MuLV) 
envelope classification. Table V contains the serum inactivation constants (K) 
obtained by reacting  nine pseudotypes with seven different  typing antisera. 
SFFV(GLV)  is  antigenically  distinct  from  all  other  MuLV  pseudotypes 
tested, while SFFV(LLV-F), SFFV(RPV),  SFFV(GiLV),  and SFFV(SimLV) 844  MUI.V  TYPE-SPECIFIC  CLASSIFICATION 
show  almost identical patterns  of reactivity with  these  typing sera.  These and 
other  distinctions  become  more  obvious  when  a  plus-minus  scheme  is  substi- 
tuted  for the observed K  values (Table VI).  "Plus"  (q-)  represents  significant 
virus  neutralization  (K  >  0.1),  and  "minus"  (--)  represents  virus neutraliza- 
tion not significantly different from control  reactions  with NMS  (K  <  0.1)  at 
the  0.1%  confidence  level.  Two  major  categories  may  be  identified  which 
correspond  to  the  G  and  FMR  subgroups.  In  addition,  the  FMR  subgroup 
can  be divided  into four types on  the basis  of distinct  neutralization  patterns. 
TABLE  VI 
Classification of the Murine Leukemia  Virus t'seudolypes  of SFFV 
Antigen  (s):~  MuLV isolate  used in  Subgroup*  Type 
the pseudotype  I§  Ii  IlI  IV  V  VI  VII 
Gross passage A  G  I  +  ...... 
Friend  FMR  2A  --  -k  q-  --  q-  --  -- 
Rowson-Parr  --  +  +  --  q-  --  -- 
Graffi  --  +  +  --  +  --  + 
SIM leukemia  -  +  +  .... 
Moloney  FM R  2B  --  --  --  +  +  --  -- 
Rauscher  FMR  2C  --  +  +  +  +  +  + 
B reyere-Moloney  --  +  +  +  +  +  + 
Rich  --  +  -c  +  +  --  + 
Buffett (334C)  FMR  2D  --  +  --  --  +  --  -- 
* This subgroup designation is based on the virus-induced cellular antigens of mouse leu- 
kemias (14, 15, 40). 
:~ Roman numerals have been arbitrarily assigned to viral envelope antigens that were de- 
tected by Gross (I), Friend LL (11), SimL (II1), Moloney (lV), Rich (V), Breyere-Moloney 
(VI), and Graffi  (VII) antisera. These antigens appear to  be antigenically distinct from one 
another, as shown above. 
§ Since rats  immunized  with  "normal"  mouse  spleen  cells  provided  serum  which  neu- 
tralized  SFFV(LLV-F),  SFFV(GLV),  and  other  SFFV(MuLV)  preparations,  the  plus- 
minus  scheme  substituted  for  the  K  values  obtained  using  (;ross  antiserum  prepared  in 
rats  (Fable V) is based  on the  following.  "Plus"  (q-)  represents  significant  virus  neutrali- 
zation,  and  "minus"  (-)  represents  virus  neutralization  not  significantly  different  from 
control reactions with rat antiserum prepared against normal mouse spleen cells (K <  0.25). 
MuLV's of type 2A express the hypothetical antigens ]I,  III, and sometimes V 
(as  detected  by  Friend  LL,  SimL,  and  Rich  antisera,  respectively),  while 
MolLV of type 2B  expresses only antigens IV and V  (as  detected by Moloney 
and  Rich  antisera).  Type  2C  contains  MuLV's  that  express  antigens  II  to  V 
inclusive,  and  sometimes  VI,  while  type  2D  is  characterized  by  antigens  1I 
and  V  only. 
It  appears  that  our  typing  sera  are  detecting  different  antigens  and  not 
different  concentrations  of  the same antigen(s).  Evidence for this  view is pro- 
vided in Table VI,  for the identification of each  antigen  or antigenic grouping 
can be exclusive of detection of all other type specificities. ROBERT  J.  ECKNER  AND  RICHARD  A.  STEEVES  845 
DISCUSSION 
Analysis of the neutralization kinetics of several SFFV(MuLV) pseudotypes 
has enabled us to classify these viruses according to their type-specific envelope 
antigens. We have made the assumption  that the classification observed here 
for SFFV(MuLV) pseudotypes can be extended in parallel to the relationships 
among the MuLV isolates used to prepare these pseudotypes. This seems to be 
a reasonable assumption, because each antiserum in our panel effectively neu- 
tralized its respective pseudotype of SFFV. However, final proof of the identity 
between our SFFV(MnLV) classification and the true MuLV classification will 
have to await a similar neutralization analysis of these MuLV's with a plaque 
assay  in vitro. 
Our method of preparing SFFV(MuLV) pseutotypes was based on the suc- 
cessful  competition in B-type mice of  an NB-tropic MuLV  over LLV-F,  the 
N-tropic helper virus for SFFV in the FV complex. Functional elimination of 
LLV-F  was  demonstrated  by  the  antigenic  stability  of  the  SFFV(MolLV) 
pseudotype (Table II),  and by the constant rate of neutralization (Fig. 4)  of 
most  pseudotypes  to  low  fractional  survival  values.  A  more  conventional 
method for preparing pseudotypes would be to "rescue" SFFV from a virus- 
negative but SFFV-transformed cell line by superinfection of the cells with a 
different MuLV. An approach like this has been  tried with  some  success  by 
Fieldsteel et al. (41, 42) but they have not described neutralization tests with 
the spleen focus assay method, and therefore we cannot be sure that they have 
actually obtained pseudotypes of SFFV. 
Our  observation  that  LLV-F  (Friend)  and  MolLV,  while  antigenically 
distinct from one another, share different antigens with LLV-R (Rauscher), is 
in keeping with some of Fink's earlier results based on in vivo protection and 
immunofluorescence (43). Rich et al. (29)  also observed a broad cross-reactivity 
among Friend, Moloney, Rauscher, and Rich viruses, but they used a heterolo- 
gous antiserum prepared in rabbits. It is now known that unabsorbed rabbit 
antisera directed against normal mouse spleen cells can "neutralize" SFFV (24), 
and, in view of this, it is remarkable that Huebner (44), with typing antisera 
from rats,  was  able  to observe distinct neutralization patterns  of the  Gross, 
Friend,  Moloney, and  Rauscher  pseudotypes of murine sarcoma virus. Levy 
et al. (45) have also demonstrated the usefulness of specific murine antiserum, 
and have shown that MolLV and GiLV are antigenically distinct. 
In the present study, rats immunized with normal BALB/c spleen cells pro- 
vided  serum  which  neutralized  SFFV(LLV-F)  as  well  as  the  SFFV(GLV) 
pseudotype. This serum activity was removed only after extensive absorption 
with BALB/c spleen cells. Further, antiserum from rats immunized with GLV- 
induced BALB/c lymphoma cells neutralized both  SFFV(LLV-F)  and  SFFV- 
(GLV). However, extensive absorption with normal BALB/c spleen  cells  pro- 
vided us with  Gross antiserum which preferentially neutralized  SFFV(GLV) 
(Table V). 
On  the  basis  of  the  findings  (that LLV-F,  MolLV,  and LLV-R  are  anti- 846  MuLV  TYPE-SPECIFIC  CLASSIFICATION 
genically distinct)  it appears that the specificity observed by  cytotoxic G  vs. 
FMR  antisera is different from that  observed by neutralization  kinetics.  We 
therefore suggest  that  the  specific antigens  revealed  by  cytotoxic tests  (14, 
15)  be  referred to  as  subgroup  specific,  while  the  MuLV  envelope antigens 
revealed by virus neutralization tests be referred to as type specific.  This is in 
keeping with evidence from several laboratories (46  48) that the cellular anti- 
gen detected in the cytotoxicity reaction is distinct from virus-bound envelope 
antigens of the corresponding MuLV. 
With  respect  to  the  cross-reactivity observed  among  those  MuLV  strains 
listed in types 2A through 2D, several points should be made: (a) LLV-F and 
RPV have a common origin and it is therefore not unexpected that these viruses 
are antigenically indistinguishable; (b) it is unusual that SimLV belongs to type 
2A since most MuLV's associated with spontaneous murine leukemias belong to 
type 1 (on the basis of the induction of G cellular antigen);  (c)  the  antigenic 
similarity  between  LLV-F  and  GiLV  may  or  may  not  be  related  to  their 
common origin from Ehrlich ascites tumors; (d) the apparent antigenic identity 
between SFFV(LLV-F) and SFFV(LLV-R) previously reported  (16)  was  not 
confirmed here, presumably due to the greater "resolving power" of neutraliza- 
tion  kinetics  when  seven  (instead  of  three)  typing  antisera  were  used;  (e) 
within type 2C,  both LLV-R and BMLV were derived from nmrine tumors, 
while RichLV was isolated from mice given extracted Friend virus RNA. This 
latter  fact,  together with  the distinct  antigenicity of RichLV,  suggests  that 
RichLV originated from the mice and not from the FV complex; Or) the 334C 
(Buffett) virus is similar to SimLV in that not all MuLV isolates from so-called 
"spontaneous" leukemias are of type 1 antigenicity. However, 334C virus does 
resemble  GLV in that we were unable to obtain virus-neutralizing antibodies 
from  immunized  mice.  In  future  studies  we  shall  examine  the  type-specific 
envelope antigens  of other known  MuLV isolates such  as  Stansly virus  and 
Mazurenko virus. It may also be feasible to prepare pseudotypes of Rauscher 
SFFV, since our stock of RV complex is now N-tropic and is helper dependent 
in B-type mice. 
Recently it has been shown that helper activity for SFFV is associated with 
avian leukemia viruses (ALV) and with feline leukemia virus (FeLV) (49), and 
also with  tissue extracts from leukemic humans  (50). To determine if ALV, 
FeLV, and helper preparations from leukemic humans (HuLH) can be used to 
prepare  pseudotypes of SFFV  is  an  important  area for future  study  which 
may increase our understanding of leukemogenesis in man. We are encouraged 
by  recent  work  (51)  that  has  demonstrated  antigenic  alteration  of  SFFV 
grown with HuLH preparations in B-type mice. These SFFV preparations are 
abbreviated SFFV(HuLH) and are neutralized by serum from patients whose 
spleens provided active HuLH extracts, but are not effectively neutralized by 
Friend typing antiserum. ROBERT  J.  ECKNER  AND  RICHARD  A.  STEEVES  847 
SUMMARY 
Coinfection of neonatal BALB/c mice with helper-dependent Friend spleen 
focus-forming virus  (SFFV),  as contained in the Friend virus  (FV)  complex, 
and  antigenically distinct  Moloney leukemia virus  (MolLV)  resulted  in  the 
recovery of a  MolLV pseudotype of SFFV,  abbreviated SFFV(MoILV). The 
antigenic  alteration  of  SFFV  was  observed  by  following  its  neutralization 
kinetics in vitro by specific Friend or Moloney typing antiserum. 
Effective  pseudotype  production  was  accomplished  only  when  N-tropic 
LLV-F (the natural helper virus in the FV complex) was inhibited in B-type 
mice  coinfected with  an  NB-tropic MolLV or  other  routine  leukemia  virus 
(MuLV)  preparation.  SFFV  pseudotypes  could  not  be  prepared  by  using 
routine viruses other than  leukemia viruses.  SFFV  prepared after two serial 
passages  in  the  presence of MolLV was  effectively neutralized  by Moloney 
antiserum, but not by Friend typing antiserum; therefore, the envelope of the 
pseudotype  virus,  SFFV(MolLV),  is  homogeneous.  Pseudotype  virus  was 
antigenically stable in  the  absence of continued mixed  infection of BALB/c 
mice with  SFFV(MoILV)  and  MolLV.  However, SFFV(MolLV)  was  easily 
converted back to the LLV-F type after only one passage  in  BALB/c mice 
coinfected  with  NB-tropic  LLV-F.  The  antigenic  interconversion  between 
LLV-F and MolLV types demonstrated that SFFV is defective with respect to 
the expression of neutralizable envelope antigens. 
Analysis  of  the  neutralizable  envelope  antigens  of  nine  SFFV(MuLV) 
pseudotypes by a panel of seven typing antisera made possible a "type-specific" 
SFFV(MuLV) envelope classification. Two major categories have been identi- 
fied which correspond to the Gross (G)  and Friend-Moloney-Rauscher (FMR) 
subgroups.  Further,  the  FMR  subgroup  was divided into four types on  the 
basis  of  distinct  neutralization  patterns.  These  results  indicated  that  the 
specificity observed by cytotoxic G  vs.  FMR  antisera is different from that 
observed by  neutralization  kinetics.  We  therefore suggest  that  the  specific 
antigens revealed by virus neutralization tests be referred to as type specific. 
We thank Mrs. Carol Houenstein and Mrs. Elizabeth Walker for able technical assistance. 
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